newsfilter
← Latest News
GlobeNewswire·

CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates

-Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial of neflamapimod in dementia with Lewy bodies (DLB), including improvement on the trial's primary outcome measure- -Plan